US Patent 9,951,016: Netupitant Crystalline Forms, Micronized Particles, and Patent Landscape

US Patent No. 9,951,016 protects selected solid-state forms of netupitant, the neurokinin-1 receptor antagonist used with palonosetron in Akynzeo. Its core protection covers a micronized, non-solvated crystalline free-base form identified by an XRPD pattern, plus a pharmaceutical composition containing that form. Separate claims cover a trifluoroethanol solvate and a formate salt.

The patent is a solid-form patent rather than a basic compound patent. Its commercial value depends on whether a generic manufacturer must use the claimed netupitant polymorph or can develop a non-infringing form, such as an amorphous material, a different polymorph, or a different salt.

What compound does US Patent 9,951,016 cover?

The claimed compound is netupitant, also known as the active NK1 antagonist in Akynzeo.

The chemical name in the claims is:

2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide.

Netupitant is approved in the United States in combination with palonosetron hydrochloride for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy and moderately emetogenic cancer chemotherapy.[1]

US 9,951,016 does not broadly claim every form of netupitant. The claims focus on crystal structure, solvation state, purity, particle size, and pharmaceutical presentation.

What are the independent claims in US 9,951,016?

The patent has five principal claim groups:

Claim	Subject matter	Key limitation
1	Micronized non-solvated crystalline netupitant free base	Less than 1% impurities and XRPD pattern substantially as shown in Figure 28
3	Pharmaceutical composition	Claim 1 solid form plus one or more pharmaceutically acceptable excipients
4	Trifluoroethanol solvate	Form II
5	Formate salt	Form III

Claims 2, 6-13 depend from these principal claims.

The most commercially significant claims are claims 1 and 3. Claim 1 reaches the active pharmaceutical ingredient. Claim 3 reaches a drug product containing that particular solid form.

How broad is claim 1?

Claim 1 is structurally narrow but commercially relevant.

It requires all of the following:

Netupitant free base.
A non-solvated crystalline form.
Micronization.
Less than 1% impurities.
An XRPD pattern substantially as shown in Figure 28.

A competing product that contains netupitant is not automatically within claim 1. The product must also contain the claimed crystalline form and satisfy the micronization, purity, and XRPD limitations.

The XRPD limitation is central. It distinguishes the claimed form from other netupitant polymorphs, amorphous netupitant, solvates, and salts. In infringement analysis, powder X-ray diffraction data would likely be used to compare the accused material with the Figure 28 pattern.

The phrase “substantially as shown” creates some flexibility because an accused sample need not reproduce every peak with mathematical identity. The analysis would typically consider peak positions, relative intensities, experimental variation, sample preparation, instrument conditions, and whether the pattern is characteristic of the patented form.

What does “micronized” mean under the patent claims?

The claims identify micronization as a required characteristic of the principal free-base form.

Claims 8 and 9 narrow the particle-size distribution:

Claim	Particle-size limitation
8	At least 90% of particles are greater than 0.01 microns and less than 500 microns
9	At least 90% of particles are greater than 0.1 microns and less than 100 microns

Claims 10 and 11 apply the same particle-size ranges to the pharmaceutical composition.

Claim 9 is narrower than claim 8 because it requires at least 90% of particles to fall between 0.1 and 100 microns. A product satisfying claim 9 would generally also satisfy the numerical range in claim 8, assuming the measurement method confirms the distribution.

The claims do not state a single measurement technique. Particle-size testing can produce materially different results depending on laser diffraction, microscopy, dynamic light scattering, dispersion medium, agglomeration control, and reporting basis. Those issues can affect both infringement and validity disputes.

What purity limits are protected?

The patent contains two purity thresholds:

Claim	Purity requirement
1	Less than 1% impurities
12	Less than 0.5% impurities
3	Less than 1% impurities in the compound used in the composition
13	Less than 0.5% impurities in the compound used in the composition

Claims 12 and 13 are narrower than claims 1 and 3. The claims do not specify whether “impurities” means total organic impurities, specified impurities, process impurities, degradation products, residual solvents, or another analytical category. The patent specification and analytical examples would control the interpretation.

A generic manufacturer could face an evidence problem if its netupitant is consistently manufactured at less than 0.5% total impurities. In that case, the narrower claims may be implicated if the solid form and other limitations are also present.

What formulations are protected by US 9,951,016?

Claim 3 covers a micronized pharmaceutical composition containing the claimed free-base form and one or more pharmaceutically acceptable excipients.

Claim 6 lists a broad range of dosage forms:

tablets;
pills;
powders;
lozenges;
sachets and cachets;
elixirs;
suspensions;
emulsions;
solutions;
syrups;
aerosols;
ointments;
soft or hard gelatin capsules;
suppositories;
sterile injectable solutions; and
sterile packaged powders.

Claim 7 narrows the composition to a tablet or capsule.

The practical focus is likely oral solid dosage forms. Akynzeo is supplied as an oral capsule containing netupitant and palonosetron hydrochloride.[1] Claims 3, 6, and 7 may therefore be relevant to a capsule product if the netupitant component uses the claimed polymorph and meets the claim limitations.

The claim language does not expressly require palonosetron. A composition containing only netupitant and excipients may fall within claim 3. A combination product containing palonosetron may also fall within the claim if all required netupitant limitations are met.

What do claims 4 and 5 protect?

Claims 4 and 5 protect different solid-state forms:

Claim 4 covers Form II, a crystalline trifluoroethanol solvate of netupitant.
Claim 5 covers Form III, a crystalline formate salt of netupitant.

These claims are independent of the free-base claims. A manufacturer could therefore infringe claim 4 or claim 5 without infringing claim 1, depending on the product’s actual solid form.

The claims do not include the less-than-1% impurity limitation, micronization requirement, or Figure 28 XRPD limitation that appears in claim 1. Their scope instead turns on whether the product is the specifically identified Form II solvate or Form III formate salt.

How does the patent distinguish among netupitant solid forms?

The patent creates a multi-form coverage structure:

Solid form	Claim treatment	Main legal issue
Non-solvated crystalline free base	Claims 1-3, 8-13	XRPD identity, micronization, purity
Trifluoroethanol solvate, Form II	Claim 4	Solvate identity and crystal form
Formate salt, Form III	Claim 5	Salt identity and crystal form
Amorphous netupitant	Not expressly claimed in supplied claims	Potential design-around
Other crystalline polymorphs	Not expressly claimed in supplied claims	Potential design-around, subject to other patents
Other salts or solvates	Not expressly claimed in supplied claims	Potential design-around, subject to other patents

This structure gives the patent multiple entry points into a solid-form dispute. A generic company must characterize its API and finished product rather than rely solely on the chemical identity of netupitant.

What is the FDA and Orange Book relevance?

Netupitant is an FDA-approved component of Akynzeo, marketed by Helsinn Healthcare SA in combination with palonosetron.[1] The relevant regulatory pathway for a generic version of the combination product is generally an ANDA, subject to the product’s reference-listed-drug status and applicable FDA requirements.

Orange Book significance depends on whether US 9,951,016 is listed for the applicable reference product and remains listed for the relevant dosage form and strength. A listed patent may require an ANDA applicant to submit a patent certification, including a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable, or will not be infringed.[2]

The patent number alone does not establish current Orange Book listing status. FDA listing must be assessed by reference product, active ingredient, dosage form, strength, and the FDA’s current patent listing data.

When does US Patent 9,951,016 lose exclusivity?

The patent issued on April 24, 2018. Its enforceable term is generally determined from the relevant nonprovisional filing date or earliest effective priority date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.[3]

The issue date does not establish the expiration date. For this patent, the legally operative expiration date must be taken from the patent’s term data and USPTO records. A generic launch analysis should separately evaluate:

ordinary patent expiration;
patent-term adjustment;
terminal disclaimers;
any patent-term extension;
Orange Book delisting or expiration;
pediatric exclusivity;
other listed patents covering Akynzeo; and
settlement restrictions.

A Paragraph IV certification can trigger litigation before expiration. The 30-month stay rules under the Hatch-Waxman Act depend on the timing and completeness of the notice and the filing of an infringement action.[2]

What Paragraph IV risks does the patent create?

A generic applicant could challenge the patent on several grounds.

Non-infringement

Potential non-infringement positions include:

use of an amorphous netupitant material;
use of a different crystalline polymorph;
use of a different salt;
use of a solvate other than Form II;
particle sizes outside the claimed ranges;
a product that does not exhibit the Figure 28 XRPD pattern;
impurity levels outside the relevant claim; or
a formulation that does not contain the claimed form.

Because claim 1 is cumulative, failure to prove any required limitation may defeat literal infringement.

Anticipation and obviousness

A validity challenge could rely on prior disclosures of:

netupitant itself;
crystalline netupitant;
the Figure 28 polymorph;
micronized netupitant;
the Form II trifluoroethanol solvate;
the Form III formate salt; or
processes that inherently produce the claimed form.

Solid-form patents are often litigated over whether the claimed polymorph was disclosed or would have been obvious based on routine crystallization screening. Evidence may include solvent selection, seeding, humidity stability, thermodynamic stability, dissolution, manufacturability, and unexpected properties.

Written description and enablement

The claims require particular crystal forms, purity levels, and particle-size characteristics. The patent specification must support those limitations and teach a skilled person how to reproduce them without undue experimentation.

What generic launch scenarios exist?

Scenario	Likely product strategy	Risk under US 9,951,016
Same crystalline free base	Match the reference product’s API form	High risk under claim 1 if XRPD, purity, and micronization match
Different polymorph	Develop another crystalline form	Lower risk under supplied claims, subject to other patents
Amorphous API	Avoid a defined crystalline form	Potentially lower risk, with formulation and stability challenges
Alternative salt	Use a different netupitant salt	Lower risk under claims 1, 4, and 5, subject to other patents
Different solvate	Avoid Form II	Lower risk under claim 4
Same API form, larger particles	Avoid micronization or particle-size limitations	Requires proof that the product does not satisfy the claim’s micronization and distribution limitations
Combination product	Netupitant plus palonosetron	Risk depends on the netupitant solid form and other listed patents

A product cannot avoid infringement merely by changing the tablet excipients if the accused composition still contains the claimed netupitant form. Conversely, a formulation change may be effective if it accompanies a genuine change in the API solid form.

How strong is the patent estate represented by US 9,951,016?

The patent is strongest against a generic that reproduces the reference product’s netupitant API and manufacturing profile. Its principal advantages are:

direct coverage of the active solid form;
composition claims reaching finished dosage forms;
dependent claims addressing commercially relevant particle sizes;
separate coverage for a solvate and a salt; and
purity limitations that may correspond to pharmaceutical-grade material.

Its limitations are equally important:

it does not claim the netupitant molecule in all forms;
claim 1 depends on XRPD identity;
the particle-size claims require analytical proof;
the composition claims depend on the claimed API form;
alternative polymorphs, amorphous material, and other salts may be available as design-around paths; and
infringement depends on the full patent family and any related formulation or method-of-use patents.

What litigation, settlement, and licensing issues affect the patent?

The supplied claim set establishes no litigation, Paragraph IV settlement, or licensing agreement. Those issues cannot be inferred from the claims.

For commercial diligence, the relevant records are:

FDA Orange Book patent listings;
ANDA Paragraph IV notices;
district court complaints;
Federal Circuit appeals;
settlement agreements filed under the Medicare Modernization Act;
USPTO assignment and maintenance records; and
licenses involving Helsinn, palonosetron, netupitant, or Akynzeo.

Helsinn’s commercial rights in Akynzeo and related intellectual property are distinct from the ownership and enforcement status of any particular patent family. Patent assignment records should be checked separately from product-label information.

Key Takeaways

US 9,951,016 is a netupitant solid-form patent.
Claims 1 and 3 target a micronized, non-solvated crystalline free-base form identified by XRPD.
Claims 4 and 5 separately protect a trifluoroethanol solvate and a formate salt.
Claims 8-11 impose particle-size distributions, while claims 12 and 13 impose a less-than-0.5% impurity threshold.
The patent is most relevant to a generic that reproduces the reference netupitant form in an oral capsule or tablet.
Alternative polymorphs, amorphous material, and non-claimed salts may offer design-around strategies, subject to other patents.
Orange Book listing, patent-term adjustment, related patents, Paragraph IV litigation, and settlements must be evaluated separately from the claim language.

FAQs

Is US 9,951,016 a patent on netupitant itself?

No. The supplied claims cover specified crystalline forms, a solvate, a salt, micronized particles, and compositions. They do not broadly cover every physical or chemical form of netupitant.

Does a netupitant capsule automatically infringe claim 3?

No. The capsule must contain the claimed non-solvated crystalline free base, satisfy the applicable purity and XRPD limitations, and meet the composition requirements.

Can an amorphous netupitant product avoid this patent?

Potentially. The supplied claims require crystalline material for the principal free-base form, although other patents or infringement theories may apply.

Are the Form II and Form III claims limited to micronized material?

The supplied claims do not expressly impose micronization or particle-size limitations on claim 4 or claim 5.

Does the patent cover Akynzeo’s palonosetron component?

No. The supplied claims are directed to netupitant forms and compositions. Palonosetron may be present in a combination product, but it is not the claimed active ingredient.

References

U.S. Food and Drug Administration. (2023). Akynzeo (fosnetupitant/palonosetron and netupitant/palonosetron) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance.
United States Patent No. 9,951,016. (2018). Crystalline forms of netupitant. United States Patent and Trademark Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015323515	⤷ Start Trial
Canada	2960599	⤷ Start Trial
China	107001275	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,951,016

Which drugs does patent 9,951,016 protect, and when does it expire?

Summary for Patent: 9,951,016